Paclitaxel activity in anthracycline refractory breast cancer patients.

Abstract

AIMS AND BACKGROUND We investigated the efficacy and tolerability of two doses of paclitaxel, 175 mg/m2 and 135 mg/m2, over a 3-hr infusion, without prophylactic G-CSF, in heavily pretreated patients with anthracycline-resistant breast cancer. Although paclitaxel may share with anthracyclines a common mechanism of drug resistance, there is evidence that the… (More)

Topics

  • Presentations referencing similar topics